Yhn ScienceBiology first seen 1 d ago, last 5 min ago, peak #5
Novo Nordisk and Eli Lilly report GLP-1 signs of slowed biological aging
Original: Novo Nordisk, Eli Lilly Report GLP-1 Signals of Slowed Biological Aging at ARDD
Novo Nordisk and Eli Lilly presented data at the Aging Research and Drug Discovery (ARDD) meeting suggesting their GLP-1 drugs may slow markers of biological aging. The news has drawn attention on Hacker News, where commenters are weighing what the findings mean for the obesity drugs' potential uses beyond diabetes and weight loss.
Why now: GLP-1 drugs like Ozempic are already hugely popular, so evidence they could slow aging extends their appeal to a much broader market.
Novo NordiskEli LillyARDDGLP-1
Rank over time, top of the chart is #1. 35 snapshots from 23 h ago to 5 min ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/2933411